Emory
Report homepage > Current
issue front page

August 30, 2004
Year-long
'academy' examines cancer drug development
By
Holly Korschun
A new Drug Development and Pharmacogenomics Academy
at Emory will offer a year-long lineup of nationally recognized basic
scientists, clinical researchers and biostatisticians presenting
an A-to-Z view of the drug pipeline and steps involved in discovering
and developing effective pharmaceuticals.
The free educational program, “A 3-D Look at Cancer Drugs: From Discovery
to Development to Delivery,” is sponsored by the Winship Cancer Institute
and the School of Medicine’s Department of Pharmacology.
Today’s inaugural lecture will feature Thomas Roberts, professor and chair
of cancer biology at Harvard Medical School and faculty dean of the Division
of Medical Sciences, speaking on “Kinase Inhibitors in Cancer Therapy and
Research.”
Roberts is considered one of the fathers of kinase therapy, the research that
led to the development of breakthrough drugs such as Gleevec for chronic myelogenous
leukemia. The program begins with a reception at 4 p.m. in Winship’s fifth-floor
conference room and will be followed by a dinner in WHSCAB plaza.
The ongoing academy schedule includes twice-monthly programs on Thursdays, beginning
at 5:30 p.m. with a light meal, followed by a lecture and round-table discussion
at 6 p.m. Lectures and discussions, delivered by leading scientists and clinicians
from throughout the country, will focus on drug discovery and preclinical development;
clinical drug development; and regulatory approval and public policy. Presenters
will share their perspectives on how the cancer community can delineate better
strategies for new drug discovery, for creating better clinical trial designs
and for improving clinical practice for patient care.
“This Drug Development and Pharmacogenomics Academy will cover all aspects
of drug development—from concept to high throughput assays all the way
through preclinical and clinical development of compounds—including pitfalls
and tricks of the trade,” said Fadlo Khuri, co-director of the academy,
Winship chief medical officer and associate director of clinical and translational
cancer research.
Haian Fu, associate professor of pharmacology and director of the Chemistry-Biology
Center for Drug Discovery, will co-direct the course.
The academy is free and open to the public. CME credit is available for individual
seminars or the entire course of lectures. More information about the academy
and a registration form are available at the Winship website: www.winshipcancerinstitute.org.
TOP
|